Loading...

A Phase 1, Single-Dose, Open-Label, 2-Period Crossover Study to Evaluate the Bioequivalence between TAK-536CCB (TAK-536 20 mg/amlodipine 5 mg) and TAK-536 20 mg plus Amlodipine 5 mg in Healthy Male Subjects - Vivli | NLM Dataset Catalog